Novo Nordisk Requests FDA to Ban Generic Drugs: The Truth Behind 400 Serious Adverse Events!

Danish pharmaceutical giant Novo Nordisk filed a formal request with the U.S. Food and Drug Administration (FDA) on Tuesday, asking the agency to ban copycats of its popular drug compounding pharmacies for weight loss and diabetes treatments. Novo Nordisk claims that the manufacturing process for these drugs is too complex to ensure its safety and quality standards.

Under U.S. regulations, pharmaceutical companies can copy brand-name drugs that are in short supply by combining, mixing or altering their ingredients to meet market demand. However, Novo Nordisk's two best-selling drugs - Wegovy and diabetes treatment Ozempic - both contain semaglutide chemically, and both have faced supply shortages in the U.S. market for much of this year.

In its filing with the FDA, Novo Nordisk asked the agency to consider placing semaglutide on a special list of drugs. Despite the shortage of these drugs, generics are difficult to produce safely due to their complexity. Novo Nordisk noted that generic versions of Wegovy, sold in incorrect doses and even found to contain unknown impurities, have caused nearly 400 serious adverse events since 2018.

In response, the FDA said it is reviewing Novo Nordisk's application and will respond directly to the drugmaker. In a statement, Novo Nordisk stressed that it wants to ensure that patients have access to FDA-approved, safe and effective cimarlutide products.

Meanwhile, the Alliance for Pharmacy Compounding, which represents pharmacy pharmacists and technicians, said in a statement that Novo Nordisk "confused the fact that semaglutide molecules are clearly difficult to make... It's relatively simple to mix with." The statement appeared to question Novo Nordisk's position.

Novo Nordisk's submission is its latest attempt to stop different businesses from selling unapproved and often cheaper versions of Wegovy. Wegovy has a monthly supply price of more than $1,000, which makes it more attractive to generics on the market. However, Novo Nordisk and rival Eli Lilly have jointly sued dozens of medical spas, weight loss clinics, compounding pharmacies and online sellers, accusing them of selling products that claim to contain active ingredients in their diet pills.

In addition, the Food and Drug Administration said this month it had agreed to reconsider a decision that barred compound companies from selling their own drugs after Eli Lilly's weight-loss and diabetes drugs were removed from the agency's shortage list. The decision could have a significant impact on generic drugs on the market.